ClinicalTrials.gg
CompletedNCT05219435VEXILLUMUpdated Apr 24, 2026

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

A Phase 2 interventional study of Nivolumab and Ipilimumab in Urothelial Cancer, sponsored by Spanish Oncology Genito-Urinary Group. Completed at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Spanish Oncology Genito-Urinary Group · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies testing nivolumab in Neoplasm Metastasis — 6 open to participants now, 16 under way, none of them phase 3. Nivolumab · Neoplasm Metastasis.

Enrollment
29th of 43
25 · median 48
Started
2022
with 1 other
Phase 2
30 of 43
4 open now
Registered
37th of 43
by date

Among the 43 studies testing nivolumab in Neoplasm Metastasis, this one is the 29th largest by enrollment, is one of 2 that started in 2022, is one of 30 in phase 2, and was the 37th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 43 studies testing nivolumab in Neoplasm Metastasis are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing nivolumab in Neoplasm Metastasis, or all of them as a file.
02

Study summary

Immunotherapy has improved clinical outcomes in metastatic urothelial carcinoma (mUC). Second-line treatment after progression to platinum-containing chemotherapy with immune checkpoint inhibitors (ICIs) have antitumor activity in advanced / metastatic UC and provide favorable safety profiles when compared with chemotherapy The study aims to determine if Nivolumab plus Ipilimumab maintenance therapy is effective in delaying disease progression in patients with unresectable locally advanced or metastatic urothelial cancer that did not progress during or following completion of first-line chemotherapy. Vexillum plans to recruit patients that achieve clinical benefit from first-line chemotherapy and may be candidates for maintenance immunotherapy to consolidate this benefit.

Read the detailed description

All enrolled patients should have received first-line chemotherapy and not progressed. After a treatment-free interval of 3-12 weeks from chemotherapy, patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.

  • Induction phase (Total of 4 cycles Q3W)

    • Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle.
    • Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
  • Consolidation phase (Cycles Q4W) ○ Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
03

Conditions studied

  • Urothelial Cancer

Browse trials for

Keywords

  • metastatic
  • unresectable locally advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Male or female subjects ≥ 18 years old.

2- Written approved by the Independent Ethics Committee (IEC), prior to the performance of any trial activities.

3- (ECOG) performance status 0 or 1.

4- confirmed, unresectable locally advanced or transitional cell carcinoma of the urothelium.

  • Also termed urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra).

    5- Stage IV disease (T4b, N0, M0; any T, N1-N3, M0; any T, any N, M1) at the start of chemotherapy.

    6- Prior first-line chemotherapy must have consisted of at least 4 cycles and no more than 6 cycles of gemcitabine plus cisplatin and/or gemcitabine plus carboplatin.

    7- Patient inclusion within the trial must occur within 3-12 weeks after the last dose of chemotherapy (3-12 weeks treatment-free interval).

    8- Only patients without progressive disease as per v1.1 guidelines after 4-6 cycles of chemotherapy will be allowed to be included. Baseline CT scan before inclusion should confirm that patients are on CR, PR or SD according to RECIST 1.1 criteria.

    9- Tumor tissue (formalin-fixed paraffin-embedded (FFPE) archival or recent acquisition) must be available at baseline.

Note: Fine Needle Aspiration [FNA] and bone metastases samples are not acceptable. If an insufficient amount of tumor tissue from an unresectable or metastatic site is available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue. This may be discussed with the PI if a new is feasible.

10- Patients with adequate normal organ and marrow function as defined below:

  1. ≥ 9.0 g/dL.
  2. (ANC) > 1500 per mm3.
  3. count ≥ 100,000 per mm3.
  4. Serum ≤ 1.5 X institutional (ULN) unless liver metastases are present, in which case it must be ≤ 2X ULN. This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology); however, they will be allowed only in consultation with their physician.
  5. Serum transaminases (, AST and GGT) ≤ 2.5X institutional upper limit of normal unless liver metastases are present, in which case it must be ≤ 3X ULN.
  6. Measured (CL) > 30 mL/min or Calculated creatinine CL > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for the determination of creatinine clearance.

    11- Female subjects of (WOCBP) must provide a negative urine pregnancy test at screening, and must agree to use a medically accepted and highly effective method (i.e. those with a failure rate less than 1%; refer to ANNEX III) for the duration of the study treatment and for 5 months after the last dose of study treatment.

A woman is considered of childbearing potential ( i.e. fertile) following menarche and until becoming unless permanently sterile. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:

  1. Amenorrheic for ≥1 year in the absence of chemotherapy and/or hormonal treatments
  2. Luteinizing hormone (LH) and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range
  3. Radiation induced oophorectomy with last menses >1 year ago
  4. Chemotherapy induced menopause with >1 year interval since last menses
  5. Surgical sterilization (bilateral oophorectomy or hysterectomy)
  6. Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
  7. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

    12- Willingness and ability of patients to comply with the protocol for the duration of the study including undergoing treatment as well as availability for scheduled visits and examinations including follow up.

Exclusion criteria

Exclusion Criteria:

  1. performance status of >1 ( \< 70%).
  2. Patients whose disease progressed by v1.1 on or after chemotherapy for urothelial cancer in the advanced or setting.
  3. Prior immunotherapy with IL-2, IFN-a or treatment with any therapy (e.g, CTLA4, PD-1, or PD-L1 targeting agent) for the unresectable metastatic setting.

    Note: Patients may have received immunotherapy in the setting as long as the last dose of adjuvant was administered at least 12 months prior to the first dose of trial treatment.

  4. Receipt of any type of systemic chemotherapy or anticancer therapy within 3 weeks before starting treatment.
  5. Previously identified allergy or to components of the study treatment formulations.
  6. History of allogeneic organ transplant.
  7. Any non-cancer treatment with vaccines used for the prevention of infectious diseases (up to 1 month before or after any dose of ipilimumab and nivolumab).
  8. Major surgery (i.e. cystectomy) less than 28 days prior to the first dose of study treatment.
  9. Patients with known symptomatic central nervous system (CNS) metastases requiring . Patients with previously diagnosed are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to inclusion, have discontinued corticosteroid treatment for these metastases for at least 4 weeks, and are neurologically stable.
  10. Subjects that have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of therapy within 28 days prior to the first dose of trial treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses (which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid).
  11. Active or prior documented disease within the past 2 years which requires systemic therapy.

    Note: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Subjects with Type I diabetes mellitus are not excluded.

  12. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis).
  13. Inadequate haematological/organ function.
  14. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, , deep vein thrombosis, or symptomatic pulmonary embolism.
  15. Persistence of any toxicities attributed to prior anti-cancer therapy, other than alopecia, that have not resolved to Grade 1 ( v5.0) or baseline before administration of study treatment.
  16. Active virus or virus.
  17. Vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivated vaccines (i.e. SARS-CoV-2 and Influenza vaccines will be permitted).
  18. Patients who have a known secondary that is progressing or has required active treatment within the past 2 years.

    Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are eligible.

  19. Pregnant or lactating females. Fertile and sexually active patients that are not willing to use the appropriate highly effective methods.
  20. Any underlying medical or psychiatric disorder, which, in the opinion of the investigator, makes the administration of ipilimumab and nivolumab unsafe or interferes with the process or trial procedures.
  21. Participation in other studies involving drug(s) within 4 weeks prior to inclusion. Observational studies are permitted.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Nivolumab plus Ipilimumab

    Patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.

    Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.

    Also known as: Opdivo

  • Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.

    Also known as: Yervoy

06

What researchers measure

Primary outcomes

  1. progression-free survival (PFS)

    PFS is defined as the time from the first dose of study treatment date until the first documentation disease progression or death from any cause, whichever occurs first. A subject who has not confirmed progression will be censored at the last known disease evaluation. Patients who have not progressed and start a new line of treatment will be censored at the date of the last adequate tumor assessment prior to starting the next line of therapy. Estimated by Kaplan Meier.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  2. progression-free survival (PFS) in PL-D1 positive patients

    subgroup analysis of PFS. Same definition of PFS as Outcome 1 applies.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

Secondary outcomes

  1. Overall Survival (OS)

    Time from the first dose of study treatment date to the date of death and the proportion/percentage of patients alive at the end of follow-up. A subject who has not died will be censored at the last known date alive. Estimated by Kaplan Meier

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  2. Clinical benefit rate (CBR)

    Percentage/proportion of patients with complete response (CR) or partial response (PR), according to ORR definition for the trial, or maintained stable disease (SD) as their overall best response throughout the study period, assessed by imaging follow-up (CT scan/MRI) and RECIST 1.1 criteria. Stable disease should be maintained for at least 4 months to be considered as a CBR event.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  3. Duration of response (DoR)

    Time from first confirmed response (CR or PR), according to ORR definition for the trial, to the date of the documented PD as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  4. Post-chemotherapy PFS (cPFS)

    defined as the time from first dosing date of chemotherapy until the first documentation disease progression or death from any cause, whichever occurs first.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  5. Post-chemotherapy OS (cOS)

    Time from first dosing of chemotherapy date to the date of death and the proportion/percentage of patients alive at the end of follow-up.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  6. Frequency of adverse events

    Number of patients experiencing adverse events from the total of patients exposed to study drug

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  7. Frequency of treatment-related adverse events

    Number of patients experiencing adverse events related to the study treatment from the total of patients exposed to study drug

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  8. Quality of life (QoL) patient reported outcomes

    Patient reported outcomes assessed through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), version 3 and the EuroQoL five-dimensions, 5 level (EQ- 5D-5L) questionnaire. Median scores for both questionnaires will be provided.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

  9. Objective response rate (ORR)

    Assessed by the investigator by imaging follow-up (CT scan/MRI) using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. This will be considered as the percentage/proportion of patients with confirmed complete response (CR) or partial response (PR) as their overall best response throughout the study period. Objective responses will be assessed by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

    Time frame: Throughout the study period, approximately 12 months per patient from first study dose.

07

Study locations

12 sites
  • Hospital Universitario Juan Ramón Jiménez
    Huelva, Andalusia 21005, Spain
  • Hospital Universitario Virgen de la Macarena
    Seville, Andalusia 41009, Spain
  • Hospital Clínico Universitario de Zaragoza
    Zaragoza, Aragon 50009, Spain
  • Hospital Universitario Son Espases
    Palma de Mallorca, Balearic Islands 07120, Spain
  • Complejo asistencial universitario de Salamanca
    Salamanca, Castille and León 37007, Spain
  • Hospital Universitario de Toledo
    Toledo, Castille-La Mancha 45004, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Catalonia 08036, Spain
  • Hospital Clínico Universitario de Santiago de Compostela
    Santiago de Compostela, Galicia 15706, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid 28041, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, Principality of Asturias 33011, Spain
  • Hospital Universitario de la Ribera
    Alzira, Valencia 46600, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2025, 36 months.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's 36 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2022
First posted
Feb 2, 2022
StartActual
Jul 6, 2022
Primary completionActual
Jul 10, 2025
CompletionActual
Jul 10, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05219435
Lead sponsor
Spanish Oncology Genito-Urinary Group
Responsible party
Sponsor
First posted
Feb 2, 2022
Start date
Jul 6, 2022
Primary completion
Jul 10, 2025
Completion
Jul 10, 2025
Last update
Apr 24, 2026

Study contacts

Guillermo de Velasco
study chair · Hospital Universitario 12 de Octubre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion